Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel anticancer agents in clinical development.

Alex A Adjei1, Eric K Rowinsky

  • 1Mayo Clinic and Foundation; Rochester, Minnesota 55905, USA. adjei.alex@mayo.edu

Cancer Biology & Therapy
|September 26, 2003
PubMed
Summary

Targeted cancer therapies offer new hope for incurable epithelial cancers. Rational drug design focusing on molecular targets improves efficacy and reduces toxicity compared to traditional chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Perils of AI-Generated Peer Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study.

Lung cancer (Amsterdam, Netherlands)·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Most approved cancer agents are DNA-active, with limited efficacy and high toxicity for common epithelial cancers.
  • Epithelial malignancies cause over 75% of cancer deaths and remain largely incurable with current treatments.

Purpose of the Study:

  • To review novel, rationally designed, target-based anti-cancer agents in clinical development.
  • To highlight the challenges and strategies for successful development of these novel therapeutics.

Main Methods:

  • Review of advances in molecular genetics and tumor biology to identify novel therapeutic targets.
  • Analysis of agents targeting signal transduction, cell cycle regulation, apoptosis, angiogenesis, and tumor stroma.
  • Discussion of clinical trial prioritization and endpoint derivation for target-based therapies.

Main Results:

  • Advances in understanding cancer pathways have revealed numerous molecular targets for therapeutic intervention.
  • Novel agents are being developed to selectively target aberrant neoplastic cells and their microenvironment.
  • Prioritization, patient stratification, and relevant endpoint derivation are critical for clinical success.

Conclusions:

  • Rationally designed, target-based agents represent a promising new frontier in cancer treatment, particularly for epithelial malignancies.
  • Overcoming challenges in clinical development is crucial for realizing the full potential of these novel therapies.

Related Experiment Videos